Publications by authors named "Daniel C Adelman"

Claim this Profile
B
Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostic, and Management Strategies.
Steve A Tilles, Daniel C Adelman, Matthew Greenhawt, Anne Marie Irani, Jay Lieberman

J Allergy Clin Immunol Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
R Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, Jeffrey G Leflein, Jonathan M Spergel, Daniel C Adelman

Allergy· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.
Justine Calise, Hannah DeBerg, Nahir Garabatos, Sugandhika Khosa, Veronique Bajzik, Daniel C Adelman

J Allergy Clin Immunol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
Christina Ciaccio, Alan B Goldsobel, Aikaterini Anagnostou, Kirsten Beyer, Thomas B Casale, Daniel C Adelman

Ann Allergy Asthma Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.
Veronique Bajzik, Hannah A DeBerg, Nahir Garabatos, Blake J Rust, Kimberly K Obrien, Daniel C Adelman

Allergy· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy.
R Sharon Chinthrajah, Stacie M Jones, Edwin H Kim, Scott H Sicherer, Wayne Shreffler, Daniel C Adelman

J Allergy Clin Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Montserrat Fernandez-Rivas, Andrea Vereda, Brian P Vickery, Vibha Sharma, Caroline Nilsson, Daniel C Adelman

Allergy· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy.
Caroline Nilsson, Amy M Scurlock, Evan S Dellon, Joshua M Brostoff, Trinh Pham, Daniel C Adelman

J Allergy Clin Immunol Pract· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis.
Nandinee Patel, Daniel C Adelman, Katherine Anagnostou, Joseph L Baumert, W Marty Blom

J Allergy Clin Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
Brian P Vickery, Andrea Vereda, Caroline Nilsson, George du Toit, Wayne G Shreffler, Daniel C Adelman

J Allergy Clin Immunol Pract· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
Jonathan O'B Hourihane, Kirsten Beyer, Allyah Abbas, Montserrat Fernández-Rivas, Paul J Turner, Daniel C Adelman

Lancet Child Adolesc Health· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.
Jack A Syage, Peter H R Green, Chaitan Khosla, Daniel C Adelman, Jennifer A Sealey-Voyksner

GastroHep· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Immunotherapy for Peanut Allergy.
Brian P Vickery, Jonathan O Hourihane, Daniel C Adelman

N Engl J Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AR101 Oral Immunotherapy for Peanut Allergy.

N Engl J Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Quality of Life in Patients with Common Variable Immunodeficiency: Why It Matters.
Daniel C Adelman, Kellee Howard

J Allergy Clin Immunol Pract· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.
Daniel C Adelman, Joseph Murray, Tsung-Teh Wu, Markku Mäki, Peter H Green

Am J Gastroenterol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.
Mitchell E Garber, Alok Saldanha, Joel S Parker, Wendell D Jones, Katri Kaukinen, Daniel C Adelman

Cell Mol Gastroenterol Hepatol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.
Daniel A Leffler, Sarah Acaster, Katy Gallop, Melinda Dennis, Ciarán P Kelly, Daniel C Adelman

Value Health· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
Joseph A Murray, Ciarán P Kelly, Peter H R Green, Annette Marcantonio, Tsung-Teh Wu, Daniel C Adelman

Gastroenterology· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
Marja-Leena Lähdeaho, Katri Kaukinen, Kaija Laurila, Pekka Vuotikka, Olli-Pekka Koivurova, Daniel C Adelman

Gastroenterology· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.
Matthew Siegel, Mitchell E Garber, Andrew G Spencer, Wendy Botwick, Pawan Kumar, Daniel C Adelman

Dig Dis Sci· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
Lee M Krug, Jeffrey Crawford, David S Ettinger, Geoffrey I Shapiro, David Spigel, Daniel C Adelman

J Thorac Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Ranjana H Advani, Herbert I Hurwitz, Michael S Gordon, Scot W Ebbinghaus, David S Mendelson, Daniel C Adelman

Clin Cancer Res· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
Elisabeth I Heath, Keith Bible, Robert E Martell, Daniel C Adelman, Patricia M Lorusso

Invest New Drugs· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Dean J Kereiakes, Arthur M Szyniszewski, Dennis Wahr, Howard C Herrmann, Daniel I Simon, Daniel C Adelman

Circulation· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis